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ABSTRACT 
Inflammatory bowel disease (IBD) is a heterogeneous group of lifelong chronic 
inflammatory diseases with variable and unpredictable disease courses which often require 
significant healthcare expenditures. There exists no uniform severity measure to capture the 
activity and the healthcare utilization of the disease. This study seeks to identify disease 
trajectories for the IBD patients based on their annual financial healthcare charges over time. We 
performed a longitudinal study of annual financial charges using a consented, prospective, 
natural history registry of 2,400 IBD patients at the University of Pittsburgh Medical Center 
from 2009 to 2013. The annual charges were calculated as the sum of inpatient admission 
charges and professional service charges, with (ChargeF) or without (ChargeR) biological 
medicine charges. Patients who completed a five-year follow-up were included in the study. The 
continuous financial charges were first categorized into sections of different price range, and 
then the data was fitted with a latent group-based zero-inflated Poisson model to identify 
different homogeneous trajectory patterns of financial charges. We identified six distinct 
trajectory groups of total annual charges obtained from each of the two calculation methods 
(ChargeF and ChargeR). We further compared between these trajectories for patient 
characteristics, disease activity indices (Harvey-Bradshaw Index and ulcerative colitis activity 
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index), disease activity markers (high-sensitivity C-reactive protein and erythrocyte 
sedimentation rate), health-related quality of life index (short inflammatory bowel disease 
questionnaire, SIBDQ), healthcare utilization (emergency department, hospitalization, and 
surgery), and corticosteroid prescriptions. 
We concluded that the healthcare financial charge could be a novel and uniform metric to 
evaluate the disease severity and the response of IBD patients to treatments. The present study is 
the first of its kind using latent group-based trajectory modeling of financial charges to identify 
distinct subsets of IBD patients with their response to treatments. The model could be used to 
determine the genetic, environmental, and other factors that influence disease severity and the 
patient’s response to medical therapies. It will provide important information for the 
development of personalized or precision medical interventions for IBD patients and the 
reduction of their health care cost.  
Public Health Relevance: 
This study proposed a new metric which could be an accurate reflection of classic disease 
activity parameters, biochemical markers of inflammation, disease activity indices, and health-
related quality of life in a cohort of patients with inflammatory bowel disease. The model 
developed would be of great significance to exploring the risk factors that influence the response 
to medical interventions. It will provide important information for the development of 
personalized or precision medical interventions for patients with inflammatory bowel disease and 
the reduction of their health care cost.  
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NOMENCLATURE 
AvePP, Average Posterior Probability 
BIC, Bayesian Information Criteria 
BMI, Body Mass Index 
CD, Crohn’s Disease 
ED, Emergency Department 
ESR, Erythrocyte Sedimentation Rate 
HBI, Harvey Bradshaw Index 
hsCRP, high-sensitivity C-reactivity Protein 
IBD, Inflammatory Bowel Disease 
MLE, Maximum Likelihood Estimator 
OCC, Odds of Correction Classification 
SIBDQ, Short Inflammatory Bowel Disease Questionnaire 
UC, Ulcerative Colitis 
UCAI, Ulcerative Colitis Activity Index 
ZIP, Zero-Inflated-Poisson 
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1.0  INTRODUCTION 
Inflammatory bowel disease (IBD) is a heterogeneous group of chronic inflammatory 
disorders affecting the gastrointestinal tract as a result of the interaction of genetic variations, 
environmental influences, intestinal microbiota alterations, and disturbances in the innate and 
adaptive immune response (Brant, 2011; McGovern et al., 2001; Triantafillidis et al., 2011). IBD 
including ulcerative colitis (UC) and Crohn’s disease (CD) often experience intermittent 
episodes of active disease alternating with variable periods of remission. The majority of IBD 
patients require hospitalization and surgery at some point in life and their response to treatments 
varies and is largely unpredictable, which often results in large financial costs (Cohen et al., 
2000; Silverstein et al., 1999). Recent estimates placed the total annual cost of CD in the US at 
$15.5 billion (Yu et al., 2008) and of UC at $14.9 billion (Cohen et al., 2010). Small groups of 
patients contribute disproportionately to healthcare expenditures and a minority of patients is 
responsible for over 50% of total costs of care. These patients often require repeat admissions 
and surgeries for refractory inflammation, complications of IBD, chronic pain, or psychosomatic 
issues(Click et al., 2015).  
To date, the genetics, environmental, and other factors that influence the response of 
patients to therapy are still poorly understood. Attempts at prognostication of disease trajectory 
and response to treatments have largely failed. Furthermore, research and clinical care for the 
IBD has been hampered by lack of a uniform severity metric that encompasses the longitudinal 
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pattern of disease. Most measures of disease activity and endoscopic scores only capture a single 
point in time. A recently published CD metric, the Lemann index, was the first attempt at 
capturing the cumulative burden of disease over time (Pariente et al., 2011; Pariente et al., 2015). 
Unfortunately, the Lemann index was considered cumbersome and requires advanced imaging to 
calculate a score. For lack of a standardized severity measure, clinicians often rely upon a 
combination of patient-reported symptoms and physician global assessment, endoscopic or 
radiographic activity, and biochemical inflammatory markers to define disease activity. These 
measures capture only direct results of gastrointestinal inflammation and fail to account for 
patient perception and experience of the disease. Consequently, researchers have utilized 
measures of healthcare utilization including hospitalizations, emergency department (ED) visits, 
surgical requirement, and advanced medical therapy to evaluate both disease and patient activity. 
While these measures are routinely available and comparable across institutions, they fail to 
differentiate the severity across patients.  
We propose a unique phenotypic metric which encompasses disease activity, healthcare 
utilization, and patient disease experience – healthcare financial charges – to define distinct 
subgroups of the IBD patients. We hypothesized that financial charges would be an accurate 
reflection of classic disease activity parameters, biochemical markers of inflammation, disease 
activity indices, and health-related quality of life in a cohort of IBD patients.  Using group-based 
trajectory models, which are increasingly popular in clinical research to assess the heterogeneity 
in response to medical interventions, we attempted to classify patients into 
different subpopulations according to their 5-year longitudinal trajectory patterns of financial 
charges collected from 2009 to 2013. The modeling was performed using the SAS macro Proc 
Traj. We examined and compared characteristics of the patients among these subpopulations. 
3 
2.0  METHODS 
2.1 STUDY POPULATION 
A natural history registry maintained at the University of Pittsburgh Medical Center 
(UPMC) for adult IBD patients (≥ 18 years old) prospectively recruited were used in this study. 
The IBD registry encompasses highly detailed, prospectively collected demographic, phenotypic, 
clinical, radiographic, and biochemical data on over 2,400 IBD patients. Both established and 
new patients (patient has not been admitted at UPMC before) were eligible for inclusion. Patients 
were eligible for inclusion if they were seen in the outpatient clinic between 2009 and 2013, had 
at least five years of follow up defined by medical charges, and were diagnosed with IBD (CD, 
UC, or IBD unclassified [IBD-U]). Patients were excluded if they were not diagnosed with IBD, 
did not have a clinical encounter between 2009 and 2013, or did not have financial charge data 
available.  
Baseline patient demographics were collected at the initial clinical encounter during the 
study period, and these included age, gender, body mass index (BMI), smoking status, and 
medical comorbidities (psychiatric disease including anxiety and/or depression, hypertension, 
hyperlipidemia, coronary artery disease, and diabetes mellitus). Comorbidities were defined by 
the ICD-9 code or physician reported problems listed in the electronic medical record (EMR). 
Disease characteristics determined at the first clinical and endoscopic encounter included disease 
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type (CD, UC, or IBD-U), duration of disease, anatomic location, and behavior according to the 
Montreal Classification (Silverberg et al., 2005), and history of prior IBD surgeries.  
Disease activity was prospectively assessed at each clinical encounter using the Harvey-
Bradshaw Index (HBI) for CD(Harvey and Bradshaw, 1980), ulcerative colitis activity index 
(UCAI) for UC(Kozarek et al., 1989), as well as high-sensitivity C-reactive protein (hsCRP) and 
erythrocyte sedimentation rate (ESR) elevation defined by local laboratory normal values (CRP: 
≥0.74 mg/dl; ESR: >40 mm/hr). Mean annual values were created for disease activity indices and 
any elevated biochemical inflammatory marker during a year was dichotomized as normal or 
abnormal for the year. Health-related quality of life was also prospectively collected at each 
clinical encounter using the validated short inflammatory bowel disease questionnaire (SIBDQ). 
Healthcare utilization parameters included emergency department (ED) use, hospital admission 
for any indication, IBD-related surgery verified by review of operative report, outpatient clinic 
appointments, and telephone encounters.  
2.2 FINANCIAL CHARGE DATA 
Financial charge data for patients in the IBD registry during 2009-2013 was obtained 
through the Center for Assistance in Research using the EMR, an information technology 
support group at the UPMC. Charge data was obtained for all healthcare services (i.e. not limited 
to gastrointestinal care) including inpatient and outpatient services at the UPMC (>20 hospitals 
and >500 outpatient clinics) for all patients in the IBD registry. The charges associated with 
outpatient medications were not included in the initial charge data. Given that the majority of 
medication charges accrue from biologic agents, we elected to impute biologic therapy charges 
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using Medicare maximal allowance charge data 2009-2013 (available at 
http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-
Drugs/McrPartBDrugAvgSalesPrice/index.html). If charge data was missing for a year but there 
were charges in the surrounding years, the missing data was assumed to be zero. If there was 
missing data for more than one consecutive year or missing data occurred on the initial or last 
year of the study period, it was left as missing. Charges were organized by total annual charge 
amounts for each year. We computed trajectory modeling using two models. For the full model 
(ChargeF), the total annual charges were calculated as the sum of impatient admission charges 
(“hospital”), professional service charges (surgery and related fees, endoscopies, radiology, 
pathology, laboratory testing, diagnostic test or procedures) and biological medicine charges. In 
the reduced model (ChargeR), imputed charges of biologic agents were not included.  
2.3 ANALYSIS PROCEDURE  
Group-based trajectory modeling has been designed to classify a population into distinct 
subgroups based on the patterns of one or several measurements taken over time. The model 
assumes that the population is composed of a mixture of j underlying trajectory groups such that 
P(𝑌𝑖) = ∑ 𝜋𝑗𝑃𝑗𝑗 (𝑌𝑖) (Jones et al., 2001), where 𝑃𝑗  (𝑌𝑖) is the probability of outcome 𝑌𝑖 given 
individual i in group j, and 𝜋𝑗 is the probability of group j. It is further assumed that (Nielsen et 
al., 2014), conditional on individual i being in group j, 𝑌𝑖 are independent for different time t so 
that   
P(𝑌𝑖) = ∑ 𝜋𝑗 ∏ 𝑃𝑡 𝑗𝑗 (𝑌𝑖)  
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In the present study, we used SAS 9.4 software and the SAS macro Proc Traj 
(http://www.andrew.cmu.edu/user/bjones/) to analyze the patterns of annual charges (from 2009-
2013) in patients with IBD. In order to fit the healthcare financial charges to an appropriate latent 
group-based trajectory model, the continuous financial charges were converted to categorical 
variables, and zero-inflated Poisson model were fitted to the categorical charge data. This model 
assume that if individual i belongs to class j, then the distribution of categorical financial charge 
is a mixture of a Poisson distribution with an excess probability of zero charges (period of 
remission). Hence, financial charge 𝑌𝑖 at time t conditional on individual i being in class j 
following distribution (Lambert, 1992; Nielsen et al., 2014) 
  (𝑌𝑖𝑡|𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖 𝑖 𝑖𝑖 𝑐𝑖𝑖𝑐𝑐 𝑗) ~ (1-𝜙𝑡𝑗)Poisson (𝜆𝑡𝑗) + 𝜙𝑡𝑗𝛿0  
where ϕt
j  is the probability of having in zero charge at time t, λt
j  is the expected 
categorical financial charge at time t, and  δ0 is a point-mass at zero.  
The probability mass function of the categorical financial charge 𝑌𝑖𝑡, therefore, has the 
following form  
𝑃(𝑌𝑖𝑡 = 𝑦𝑖𝑡|𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖 𝑖 𝑖𝑐 𝑖𝑖 𝑐𝑖𝑖𝑐𝑐 𝑗) 
= �
�1 −𝜙𝑡𝑗�𝑒−𝜆𝑡𝑗 + 𝜙𝑡𝑗      𝑦𝑖𝑡 = 0
�1 − 𝜙𝑡𝑗� 𝑒−𝜆𝑡𝑗(𝜆𝑡𝑗)𝑦𝑖𝑡𝑦𝑖𝑡!               𝑦𝑖𝑡 > 0 
where parameters 𝜙𝑡
𝑗 is the probability of having zero charge, and 𝜆𝑡
𝑗 is the expected 
categorical categorical financial charge for individual i in group j at time t.   
This equation provides the estimated mean or expected value, 𝜇𝑡
𝑗, of the categorical 
charge 𝑌𝑖𝑡 at time t of an individual i being in group j, where 
𝜇𝑡
𝑗 = 𝐸(𝑌𝑖𝑡|𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖 𝑖 𝑖𝑖 𝑐𝑖𝑖𝑐𝑐 𝑗) = (1 − 𝜙𝑡𝑗)𝜆𝑡𝑗. Note that 
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The expected categorical financial charge 𝜆𝑡
𝑗 are modeled (Nielsen et al., 2014) by either 
the quadratic predictor functions: 
log(𝜆𝑡
𝑗)=β0𝑗 + β1𝑗𝑡 + β2𝑗𝑡2 
or the cubic predictor functions: 
log(𝜆𝑡
𝑗)=β0𝑗 + β1𝑗𝑡 + β2𝑗𝑡2 + β3𝑗𝑡3 
where for each group j, the unknown values 𝛽𝑖𝑗 are needed to be estimated. 
Probabilities 𝜙𝑡
𝑗 model the amount of zero inflation, that is, the excess probability of 
individual i having in a no charge. They are modeled by predictor functions given as either a 
logit-linear function (Nielsen et al., 2014): 
  logit(𝜙𝑡
𝑗)= log( 𝜙𝑡𝑗
1−𝜙𝑡
𝑗)=𝛼0𝑗 + 𝛼1𝑗t 
or a logit-quadratic function:  
logit(𝜙𝑡
𝑗)= log( 𝜙𝑡𝑗
1−𝜙𝑡
𝑗)=𝛼0𝑗 + 𝛼1𝑗t + 𝛼2𝑗𝑡2 
or a form that is proportional to log(𝜙𝑡
𝑗) as in the zero-inflated Poisson model with 
parameter τ of Lambert (Lambert, 1992): 
logit(𝜙𝑡
𝑗)= log( 𝜙𝑡𝑗
1−𝜙𝑡
𝑗)=-𝜏𝑗 log(𝜆𝑡
𝑗) 
where 𝛼𝑖𝑗 and 𝜏𝑗 are unknown values to be estimated. 
Combining these equations, the overall likelihood function is given by 
𝐿𝑘(𝜃)=∏ ∑ 𝑝𝑗 ∏ [(1 − 𝛷𝑡𝑗)𝑒−𝜆𝑡𝑗 (𝜆𝑡𝑗)𝑦𝑖𝑡𝑦𝑖𝑡!𝑇𝑡 + 𝛷𝑡𝑗𝐼 (𝑦𝑖𝑡 = 0)]𝐽𝑗=1𝑁𝑖=1  
where 𝜃 is a vector of all the unknown parameters (Nielsen et al., 2014). 
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2.3.1 Model selection 
The model selection procedure with Proc Traj is an iterative model-fitting and decision 
process that requires both statistical and subjective determinations. We followed a two-stage 
model selection process as suggested by Nagin (Nagin, 2005) that the number of trajectory 
groups will be determined in the first stage and the best polynomial trajectory function (constant, 
linear, quadratic, or cubic) will be determined and the Bayesian Information Criteria (BIC) value 
will then be calculated in the second stage.  
BIC is calculated as in equation:    BIC = log(L) – 0.5k log(N)         
Where L is the value of the model’s maximum likelihood, N is the sample size, and k 
refers to the number of parameters in the model.  
In SAS output, two values of the BIC are calculated based on: 1) the number of subjects, 
and 2) the total number of observations across time. The true BIC lies within these two BIC 
values.  We started by determining the best one-group model and then increased the number of 
groups one by one until the maximum logical number of groups was reached or the BIC value 
started to rise. In the final step, we selected the final best model that has the lowest absolute BIC 
value (Roeder et al., 1999). Other factors in making such selection were clinical knowledge and 
reasonable judgment (e.g., group size is reasonably large, >5%) (Nagin, 2005) and ΔBIC which 
is the difference of BICs between two models with different numbers of trajectory groups 
(ΔBIC=ΔBIC𝑐𝑐𝑐𝑐𝑐𝑒𝑐 − ΔBIC𝑛𝑛𝑐𝑐). In accordance with recommendations of Jones et al.(Jones et 
al., 2001), 2ΔBIC larger than 10 is considered a strong evidence in favor of the model with a 
larger number of BIC. 
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2.3.2 Model adequacy assessment  
The model adequacy was assessed using several diagnostics suggested by Nagin (2005). 
The first one is based on the average posterior probability (AvePP) calculated for each trajectory 
group. The minimum rule-of thumb, according to Nagin, is that AvePP should be at least 0.7 for 
all the trajectory groups. The second diagnostic static odds of a correct classification (OCC) for 
each trajectory group is defined by OCC = [(AvePP/(1-AvePP)] / [π/(1- π)], where π is the 
estimated group probability. The numerator of OCC is the odds of a correct classification into the 
corresponding trajectory group on the basis of the maximum probability classification rule. The 
denominator of OCC, 𝜋
1− 𝜋 is the odds of correct classification based on the random assignment, 
with the probability of assignment to this group equals the estimated group membership.  An 
OCC value greater than 5.0 for all trajectory groups indicates that the model has high assignment 
accuracy. The third diagnostic is based on the estimated group probability (π) versus the 
proportion (P = 
𝑛
𝑁
) of the sample assigned to the group. If individuals are assigned to groups with 
perfect certainty, P and π become identical. Therefore, the model adequacy can be evaluated by 
determining whether values P and π are reasonably close. Finally, the precision of the estimated 
group memberships can be evaluated using confidence intervals. A narrow confidence interval 
means that the probability is accurately estimated. However, there are no formal criteria for 
determining when a confidence interval is sufficiently narrow to be considered accurate for the 
estimate. 
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2.4 ETHICAL CONSIDERATIONS  
 
Enrollment in and use of the IBD registry (Protocol #0309054) as well as the current 
registry analysis (Protocol #15050428) were approved by the Institutional Review Board at 
University of Pittsburgh.  
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3.0  RESULTS 
3.1 GROUP-BASED TRAJECTORY MODELING OF LONGITUDINAL 
HEALTHCARE FINANCIAL CHARGES WITH BIOLOGICAL MEDICINE CHARGES 
EXCLUDED 
3.1.1 Descriptive analysis 
There was financial charge data of 2,204 IBD patients in the registry. The analysis 
included a total of 1,600 IBD patients (mean ± SD age: 47.0 ± 15.7 years, 53.4% female) with 5-
year complete financial charges. The vast majority of the patients were white (96.8%), 60% of 
patients were married, and nearly 50% patients had full-time jobs (Table 1). 
As shown in Table 2, the total annual charges (ChargeR, including ‘hospital’ and 
‘professional service’ charge) for IBD patients are highly skewed. The spending on health care 
services is highly concentrated among small proportion of patients with very high usage (Figure 
1). For instance, 9.6% of patients had 80% of health care expenditure in 2009, and the lower 
50% of patients had $0.75 million of health care compared to $35 million in total. Because there 
were many low charges, no transformation could bring annual charges to approximately a normal 
distribution.  
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  Table 1. Demographic statistics for the population studied. 
 
Categorical 
 
Coding n Percent 
Sex 
missing=63 
1=Male    716 46.6 
2=Female    821 53.4 
Race 
missing=80 
1=White 1,472 96.8 
2=Others      48   3.2 
Marital 
missing=371 
1=Single    427 34.7 
2=Married    740 60.2 
3=Divorced      62   5.1 
Employment 
missing=79 
1=Full time    746 49.1 
2=Unemployed    285 18.7 
3=Retired    144   9.5 
4=Part time      37   2.4 
5=Student   118   7.8 
6=Unknown   191 12.6 
Continuous 
 
Min/max n Mean (SD) 
 Age (in years) 
missing=63 
 
 
 
 
18/96 1,537 47.0(15.7) 
 
 
Table 2. Descriptive statistics for ChargeR* from 2009 to 2013. 
 
Years Minimum 25th  
percentile 
Mean Median 75th  
percentile 
Maximum 
2009 0 658 22,345 2,551 5,708 1,884,564 
2010 0 338 23,489 2,361 5,265 1,390,001 
2011 0 363 19,712 2,338 5318 1,509,565 
2012 0 320 26,285 2,350 5,178 2,839,320 
2013 0 429 22,694 2,293 5,197 2,103,697 
*ChargeR presented is in the US dollars. 
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Figure 1. Cumulative distribution of total annual financial charges (ChargeR) from 2009 to 
2013. 
 
 
The Proc Traj provides options for modeling three different distributions (censored 
normal, Zero-Inflated Poisson, and logistic model). In order to fit the data to an appropriate 
group-based trajectory model via Proc Traj, we converted the continuous charges into 41 
categorical groups using the cut points described in Table 3. Figure 2 shows the distribution of 
new categorical ChargeR. The new categorical annual charges were also highly skewed. The 
individual trend lines plotted with the categorical annual charges for the first 5 patients are 
presented in figure 3.  The ZIP model of Proc Traj was appropriate for the analysis since the 
count data were employed for the new categorical financial charges. 
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Table 3. Conversion of continuous financial charges to categorical variables. 
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Figure 2. Frequency distribution of categorical annual charges (ChargeR) from 2009 to 
2013. 
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Figure 3. Categorical ChargeR trend lines from 2009 to 2013 for the first 5 IBD patients. 
3.1.2 Trajectory model development using ZIP model with ChargeR  
In selecting the optimum number of groups, the most common approach is to optimize 
the BIC by computing the corresponding maximum likelihood estimator (MLE) using the Proc 
Traj procedure (Jones and Nagin, 2007; Jones et al., 2001). Here we found that the BIC 
monotonically increased when more groups were added (Table 4). Thus, BIC alone is not useful 
in identifying the best model (Eggleston et al., 2004; Nagin, 2005). It has been suggested that 
subject-specific judgement should be combined with BIC to decide the group number (Blokland 
et al., 2005; Loughran and Nagin, 2006; Nagin and Odgers, 2010). By examining models ranging 
from 1 to 8 groups, we noticed that the additional groups in the 7- and 8-group models offered no 
extra explanation power clinically when compared with the 6-group model. Together with other 
criteria such as reasonable sample size for each group membership (>5%), we decided to use the 
6-group model since it provided the similar intuition with less complexity.   
17 
The 6-group model was then refined until the highest polynomial’s coefficient for each 
trajectory group was significantly different from 0. Our final model had a flat line for group 1, 
one quadratic order for group 2, three cubic orders for the groups 3, 4 and 5, and a linear order 
for the 6th group (Table 4). The BIC value for this model was -27029.93 (N=1600), and the best 
fit among all the other 6-group models had different polynomial’s coefficients (Figure 4).  
 
 
 
Table 4. Comparison of BICs from selected ZIP models fitted using ChargeR. 
 
No. of  
Groups Order* Iorder* 
BIC1  
(N=1,600) 
BIC2  
(N=8,000) 
1 2 2 -44608.52 -44613.35 
2 2 2 2 -34503.79 -34511.83 
3 2 2 2 2 -32042.06 -32053.32 
4 2 2 2 2 2 -29630.29 -29644.78 
5 2 2 2 2 2 2 -28319.80 -28337.51 
6 2 2 2 2 2 2 2 -28274.48 -28295.40 
7 2 2 2 2 2 2 2 2 -27736.07 -27760.21 
8 2 2 2 2 2 2 2 2 2 -26730.99 -26758.35 
6 0 2 3 3 3 1 2 -27029.93 -27050.85 
*Order: Polynomial (0=intercept, 1=linear, 2=quadratic, 3=cubic) for each group; Iorder: 
Polynomial (0=intercept, 1=linear, or 2=quadratic) zero inflation probability logit for each group. 
BIC1 relates to the overall sample size and BIC2 related to the subject sample size. 
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The average data is represented by the solid lines and the predicted trajectories are represented 
by the dashed lines. 
 
Figure 4. Graphical output from Proc Traj showing a six-group of the categorical annual 
ChargeR trend patterns in IBD patients. 
 
Using the maximum probability rule, the majority of the patients (52.1%) were located in 
group 1 consisting of individuals who consistently incurred low charges during the follow up 
time (Figure 4). These patients were presumed to have no new active symptoms and remained 
stable for years. Group 2 (8.1%) had low charge in 2009 with a slight increase in the next 3 
years, suggesting that the patients in this group were developing active symptoms and requiring 
healthcare expenditures during that period of time. The largest increase in the expenses occurred 
in 2013. Longer observation time would be needed to evaluate the potential benefit effects of the 
interventions. Patients in groups 3 (9.3%) and group 5 (9.4%) all responded very effectively to 
treatments received, as the financial charges in all subsequent years were dropped remarkably to 
low level. Patients in group 4 (12.1%) started to develop active symptoms in 2010, after two 
years of moderate medical interventions in 2011 and 2012, chargeR dropped to a low level in 
2013. Among all the groups, group 6 (9.0%) had the highest basal level of charges in 2009. 
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Importantly, the cost of medical services for this group of patients remained at high level over 5 
years. Patients in group 6 likely had severe disease and poor response to medical and surgical 
treatments. Therefore, future studies to identify genetic and environmental risk factors associated 
with the poor outcome of this group of patients will be particularly important for the 
development of novel therapeutic strategies and the reduction of healthcare utilization. 
3.1.3 Evaluating the fit of the model 
The fit of the model was evaluated using several diagnostics suggested by Nagin (Nagin, 
2005), and the results are presented in Table 5. The lowest average posterior probability was 
0.950, far greater than the recommended value of 0.7. Furthermore, the lowest value for the OCC 
was 59.2, which was also much larger than the recommendation of 10 as a general guideline. The 
data indicate that the model assigned patients to different trajectory groups with very high 
certainty. In addition, the probability of group membership (π) and the proportion assigned to 
each group using the maximum probability rule (P), are almost identical for each group. Finally, 
the 95% confidences of the estimated group memberships (πj) were also relatively narrow for 
each group; less than 0.025 plus or minus πj. 
Table 5. Diagnostics of model (fitted using ChargeR) performance. 
 
*AvePP, average AvePP, average Posterior Probability; OCC, odds of correct classification;  
P, actual proportion of subjects assigned to each trajectory group using the maximum probability rule. 
Trajectory 
Group 
Group 
Membership π  
 
N 
 
AvePP* OCCj* P* 
95% 
Confidence 
Interval 
1 0.521 838 0.985 59.2 0.524 (0.496, 0.546) 
2 0.081 128 0.961 279.4 0.08 (0.067, 0.095) 
3 0.093 149 0.950 185.4 0.093 (0.078, 0.108) 
4 0.121 193 0.956 159.7 0.121 (0.104, 0.138) 
5 0.094 150 0.964 257.5 0.094 (0.079, 0.109) 
6 0.09 142 0.981 522.5 0.089 (0.075, 0.105) 
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3.1.4 Demographic and comorbidity characteristics among the identified 
trajectory groups 
Extensive demographic and clinical data collected from 1537 (96.1%) patients were 
analyzed. There were no significant difference in age, gender and marital status among the 
charge trajectory groups. The chi-squared test demonstrated a statistically significant difference 
in employment status in the distribution of charge trajectory groups (p<0.01) (Table 6). The 
unemployment rates were higher in Groups 3 and 6. 
No significant association between BMI and trajectory membership was observed. There 
was significantly more comorbid anxiety and/or depression (p<0.0001), diabetes mellitus 
(p=0.003), and hypertension (p<0.0001) in Groups 5 and 6 as compared to other groups. Groups 
5 and 6 also had significantly more CD (p<0.0001), perianal disease (p=0.002), and more 
extensive UC (p<0.0001) as compared to the other groups. Patients in Group 6 also had 
significantly more prior IBD surgery (p<0.0001) (Table 6).  
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Table 6. Patients characteristics for each financial charge trajectory subgroup. 
Trajectory Group 1 2 3 4 5 6 P value 
No., % 794 (51.7) 121 (7.9) 146 (9.5) 186 (12.1) 149 (9.7) 141 (9.2) -- 
Female % 400 (50.4) 62 (51.2) 80 (54.8) 108 (58.1) 91 (61.1) 80 (56.7) 0.11* 
Age, median (IQR) 46 (24) 46 (25) 43.5 (27) 43.5 (24) 46 (23) 46 (27) 0.95† 
BMI, median (IQR) 25.6 (6.3) 25.9 (8.4) 24.8 (6.8) 26.5 (8.6) 25.7 (7.5) 26.2 (8.2) 0.38† 
Smoking Status, % 
Never 
Former 
Current 
 
554 (74.0) 
143 (19.1) 
52 (6.9) 
 
95 (79.2) 
19 (15.8) 
6 (5.0) 
 
105 (75.0) 
27 (19.3) 
8 (5.7) 
 
129 (70.9) 
44 (24.2) 
9 (5.0) 
 
103 (70.1) 
36 (24.5) 
8 (5.4) 
 
85 (61.2) 
41 (29.5) 
13 (9.4) 
0.08* 
Comorbid, % 
Psychiatric  
DM 
HLD 
HTN 
CAD 
Thyroid 
Disorder 
 
160 (20.2) 
34 (4.3) 
81 (10.2) 
138 (17.4) 
11 (1.4) 
51 (6.4) 
 
25 (20.7) 
7 (5.8) 
12 (9.9) 
23 (19.0) 
1 (0.8) 
6 (5.0) 
 
36 (24.7) 
8 (5.5) 
20 (13.7) 
26 (17.8) 
4 (2.7) 
15 (10.3) 
 
49 (26.3) 
11 (5.9) 
22 (11.8) 
44 (23.7) 
3 (1.6) 
5 (2.7) 
 
57 (38.3) 
17 (11.4) 
20 (13.4) 
45 (30.2) 
6 (4.0) 
10 (6.7) 
 
51 (36.2) 
16 (11.3) 
21 (14.9) 
47 (33.3) 
6 (4.3) 
10 (7.1) 
 
<0.0001* 
0.003* 
0.45* 
<0.0001* 
0.09* 
0.12* 
Marital Status, % 
Single  
Married 
Divorced 
 
222 (34.8) 
390 (61.1) 
26 (4.1) 
 
28 (33.7) 
49 (59.0) 
6 (7.2) 
 
47 (37.6) 
75 (60.0) 
3 (2.4) 
 
48 (33.8) 
84 (59.2) 
10 (7.0) 
 
40 (31.5) 
81 (63.8) 
6 (4.7) 
 
42 (36.8) 
61 (53.5) 
11 (9.7) 
0.30* 
Employment Status, % 
Full Time 
Unemployed 
Retired 
Part Time 
Student 
Other 
 
396 (49.7) 
111 (13.9) 
61 (10.0) 
21 (2.7) 
64 (8.2) 
125 (16.1) 
 
65 (44.3) 
23 (21.5) 
10 (9.4) 
3 (2.5) 
8 (6.6) 
12 (10.0) 
 
65 (42.1) 
29 (28.3) 
21 (8.6) 
4 (2.7) 
9 (6.2) 
18 (12.3) 
 
101 (56.6) 
36 (16.6) 
22 (7.2) 
3 (1.6) 
13 (7.0) 
11 (5.9) 
 
67 (51.9) 
43 (17.3) 
9 (12.2) 
3 (2.0) 
11 (7.4) 
16 (10.7) 
 
52 (44.2) 
43 (26.7) 
21 (9.7) 
3 (2.1) 
13 (9.2) 
9 (6.4) 
<0.0001* 
Disease, % 
CD 
UC 
IBD-U 
 
405 (51.0) 
343 (43.2) 
43 (5.4) 
 
70 (57.9) 
47 (38.8) 
1 (0.8) 
 
87 (59.6) 
52 (35.6) 
6 (4.1) 
 
110 (59.1) 
65 (34.9) 
9 (4.8) 
 
111 (74.5) 
34 (22.8) 
4 (2.7) 
 
93 (66.0) 
42 (29.8) 
5 (3.5) 
<0.0001* 
Duration, years median 
(IQR) 
13.5 (12) 14 (20) 12 (11) 14 (14) 13 (12) 14 (12.5) 0.30* 
CD Location‡, % 
Ileal 
Colonic 
Ileocolonic 
Upper 
 
103 (27.1) 
78 (20.5) 
198 (52.1) 
16 (4.2) 
 
21 (31.8) 
7 (10.6) 
38 (57.6) 
2 (3.0) 
 
21 (25.3) 
19 (22.9) 
43 (51.8) 
3 (3.6) 
 
33 (32.4) 
18 (17.6) 
49 (48.0) 
4 (3.9) 
 
32 (29.9) 
26 (24.3) 
48 (44.9) 
5 (4.7) 
 
26 (28.6) 
14 (15.4) 
51 (56.0) 
8 (8.8) 
0.55* 
0.82* 
0.22* 
0.79* 
0.55* 
Perianal‡, % 69 (17.4) 4 (5.8) 20 (23.3) 18 (17.1) 32 (29.1) 21 (22.6) 0.002* 
CD Behavior‡, % 
Inflammatory 
Stricturing 
Penetrating 
 
160 (45.1) 
108 (30.4) 
87 (24.5) 
 
33 (50.8) 
22 (33.8) 
10 (15.4) 
 
25 (30.9) 
30 (37.0) 
26 (32.1) 
 
45 (45.0) 
32 (32.0) 
23 (23.0) 
 
37 (35.6) 
35 (33.7) 
32 (30.8) 
 
37 (40.2) 
30 (32.6) 
25 (27.2) 
0.27* 
0.15* 
0.70* 
0.13* 
UC Extent ‡, % 
Proctitis 
Left-Sided 
Extensive 
 
20 (7.0) 
104 (36.4) 
162 (56.6) 
 
4 (9.5) 
15 (35.7) 
23 (54.8) 
 
2 (4.2) 
17 (35.4) 
29 (60.4) 
 
6 (10.9) 
23 (41.8) 
26 (47.3) 
 
1 (4.2) 
5 (20.8) 
18 (75.0) 
 
1 (2.6) 
3 (7.7) 
35 (89.7) 
0.01* 
0.52* 
0.002* 
<0.0001* 
Prior IBD Surgery, % 253 (31.9) 49 (40.5) 50 (34.2) 64 (34.4) 62 (41.6) 74 (52.5) <0.0001* 
BMI: body mass index; DM: diabetes mellitus; HTN: hypertension; HLD: hyperlipidemia; CAD: 
coronary artery disease; CD: Crohn’s disease; UC: ulcerative colitis; IBD-U: inflammatory bowel disease 
unclassified 
* Chi-squared test; †median test. 
‡Location data missing in 47 CD patients; perianal disease data missing in 16 CD patients; Behavior data 
missing in 79 CD patients; and Extent data missing in 89 UC patients. 
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3.1.5 Disease activity and quality of life analysis based on trajectory group 
memberships 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Inflammatory biomarkers, IBD disease activity indices and health related quality 
of life in trajectory groups. 
 
To assess whether the financial charge data accurately reflect the IBD disease activity, we 
first evaluated hsCRP and ESR, two biomarkers of inflammation, for each trajectory group and 
plot the proportion of patients with elevated maker against time (Figure 5 A, B). Annual trend 
patterns of elevated hsCRP and ESR mirrored group trajectory over the five-year period. Group 
6 patients with persistently high chargeR also had increased annual elevated hsCRP and ESR 
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patterns as compared to the other groups. Group 6 also had the highest proportion of hsCRP 
elevation (72.3%) and ESR (79.4%) over the five-year period. Conversely, patients with 
consistently low chargeR (Group 1) had the lowest rates of abnormal hsCRP and ESR both 
annually and over the five-year period (24.7% and 34.1% respectively). Examining those groups 
with fluctuation in their charge patterns (Groups 2-5), the timing of hsCRP and ESR elevation 
was reflected in simultaneous elevated charge patterns.  
Similarly, annual patterns of disease activity indices were markedly similar to the 
patterns of charges. Median annual values of HBI and UCAI were reflected in the group 
trajectory membership (Figure 5C and D) as patients in Group 6 displayed a persistently elevated 
median HBI, reflective active disease, over the five years as compared to peers. On the other 
hand, patients in Group 1 had decreased median HBI and UCAI as compared to other groups. 
Similar to biochemical markers of inflammation, temporal variations in charges were well 
reflected in patterns of disease activity indices. 
The health-related quality of life measured by SIBDQ revealed an inverse and temporal 
association with the charge group status (Figure 5E). Patients in Group 6, with persistently high 
charges demonstrated consistently low SIBDQ scores denoting a lower quality of life. 
Conversely, patients in Group 1 with perpetually low charges demonstrated a higher quality of 
life annually over the five-year period as compared to the other groups. Temporal trends in 
charges in Groups 2-5 were mirrored by deterioration or improvement in SIBDQ at the 
respective time points.  
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3.1.6 Healthcare utilization analysis among identified trajectory groups  
Annuals rates of emergency department (ED) usage, inpatient hospitalizations, and IBD-
related surgeries were each well reflected by the financial charge group status (Figure 6). Group 
6 had consistently higher annual rates of ED usage and hospitalization as compared to other 
groups, and Group 1 patients had the lowest annual rates of ED usage and hospitalization. 
Furthermore, Group 6 had the highest overall proportion of patients who utilized the ED 
(95.0%), experienced hospitalization (97.2%), or underwent IBD-related surgery (64.5%) over 
the five years. On the other hand, Group 1 had the lowest five-year rates of ED use (21.0%), 
hospitalization (5.5%), and surgery (2.0%). Similar to other parameters, temporal trends in 
healthcare utilization were almost identically mirrored in the charge group membership for 
Groups 2-5.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Healthcare utilization in established trajectory groups.   
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3.1.7 Corticosteroid requirement based on trajectory group memberships 
Corticosteroids are used to treat acute (sudden onset and/or short duration) flare-ups. The 
use of corticosteroids over the five-year period also correlated to charge group membership 
(Figure 7). Group 6 had the highest rates of corticosteroid use for all years except for year 5 
when Group 2 overtook in rates of steroids use and the total charges. Over the five-year period, 
Group 6 had the highest proportion of patients receiving corticosteroids (70.9%).  Group 1 had a 
persistently low rate of corticosteroid use and lowest cumulative steroid exposure (29.6%) while 
Groups 2-5 had variations in their corticosteroid prescriptions reflected by simultaneous 
fluctuation in their charge trajectory. 
 
  
 
 
Figure 7. Corticosteroid requirement in among established trajectory groups. 
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3.2 GROUP-BASED TRAJECTORY MODELING OF LONGITUDINAL 
HEALTHCARE FINANCIAL CHARGES WITH BIOLOGICAL MEDICINE 
CHARGES. 
 
Although the exact causes of IBD are unknown, genetic, environmental, and immune 
response factors have been proposed. Among those, the immune system plays a major role in the 
development of active disease. Recently, a variety of   biological therapies have been developed 
for the treatment of IBD. These medications have changed the way physicians treat IBD patients. 
The medications, however, are very expensive, with treatment costs ranging from US$3,000 to 
$8,000 per infusion. In order to get a more complete estimation of disease severity using medical 
cost, we re-calculated the total annual charge (ChargeF) using “hospital” charges, “professional 
service” charges and imputed biological medicine charges (Table 7). Similar to ChargeR, the 
distributions of ChargeF were also highly skewed. Around 12.5% patients had 80% of health care 
expenditure in 2009, and the lower 50% patient had $0.86 million of health care cost as 
compared to $40.14 million in total (Figure 8). Similarly, the continuous ChargeF were 
converted to categorical variables in order to use the appropriate model via Proc Traj.  Figure 9 
demonstrated the frequency distribution of the categorical charge variables. The individual 
ChargeR trend patterns for the first 5 patients are shown in Figure 10.  
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Table 7. Descriptive statistics for ChargeF * from 2009 to 2013. 
 
Years Minimum 25
th 
percentile Mean Median 
75th 
percentile Maximum 
2009 0 771 25,087 2,827 15,270 1,908,866 
2010 0 383 25,875 2,618   9,207 1,390,001 
2011 0 410 22,510 2,710 13,170 1,534,226 
2012 0 447 30,355 3,373 20,156 2,839,320 
2013 0 429 27,317 3,262 20,396 2,103,697 
 *ChargeF presented is in the US dollars. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Cumulative distribution of total annual financial charges (ChargeF) from 2009 to 
2013. 
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Figure 9. Frequency distribution of categorical annual charges (ChargeR) from 2009 to 
2013. 
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Figure 10. Annual financial charge data using ChargeF (with different symbols) from 2009 
to 2013 (connected in line) for the first 5 IBD patients. 
 
Using the same model development strategy mentioned in 3.1.2, we set the optimum 
trajectory group number to 6, which provided sufficient explanatory power with less complex 
(Table 8). The highest polynomial’s coefficient for each trajectory group was then refined for 
the best fit. Our final model had cubic orders for the first 5 groups, and a linear order for the 6th 
group (Table 8). The BIC value for this model was -28596.7 (N=1600), and the best fit among 
all the other 6-group models had different polynomial’s coefficients. 
Table 8. Comparison of BICs from ZIP models fitted using ChargeF. 
No. of 
Groups 
Order* Iorder* BIC1 
(N=1600) 
BIC2 
(N=8000) 
1 2 2 -46132.03 -46136.86 
2 2 2 2 -35295.62 -35303.67 
3 2 2 2 2 -32210.58 -32221.85 
4 2 2 2 2 2 -30625.99 -30640.48 
5 2 2 2 2 2 2 -29682.82 -29700.53 
6 2 2 2 2 2 2 2 -29022.17 -29043.10 
7 2 2 2 2 2 2 2 2 -28596.01 -28620.16 
8 2 2 2 2 2 2 2 2 2 -28217.32 -28244.68 
6 3 3 3 3 3 1 1 -28596.7 -28620.09 
*Order: Polynomial (0=intercept, 1=linear, 2=quadratic, 3=cubic) for each group; Iorder: 
Polynomial (0=intercept, 1=linear, or 2=quadratic) zero inflation probability logit for each group. 
BIC1 relates to the overall sample size and BIC2 related to the subject sample size. 
0
12,000
45,000
160,000
1,000,000
2009 2010 2011 2012 2013
Year of Follow up 
1
2
3
4
5
To
ta
l f
ul
l a
nn
ua
lc
ha
rg
e
30 
 
 
 
 
 
 
 
 
 
The average data is represented by the solid lines and the predicted trajectories are represented 
by the dashed lines. 
 
Figure 11. Graphical output from Proc Traj showing a six-group of the categorical annual 
ChargeF trend patterns in IBD patients.  
 
Using the maximum probability rule, around 40.1% patients were assigned to Group 1 
which presumably consisted of individuals who had no active symptoms and remained stable 
from 2009 to 2013 (Figure 11). Group 2 (9.4%) had active symptoms in 2009 and 2010, and 
responded well to the medical interventions, as the healthcare charge dropped to low levels in 
2012 and 2013. Group 3 (9.6%) has low basal charge in 2009, which markedly increased in the 
next 2 years and remained high afterward. This suggests that patients in Group 3 developed 
active symptom during the follow-up time, and they did not response well to the medical 
interventions. Future studies will be necessary for this sub-group of patients to identify the 
factors that are responsible for the high expenditure. Group 4 was estimated to comprise 17.1 % 
of total sample population. Patients in this group were developing active symptoms from 2009 to 
2013 as reflected by the increasing financial charges, and longer observation time will be needed 
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to evaluate the potential benefit effects of the interventions. Patients in Group 5 (10.1%) had 
active symptoms in 2009, and have undergone extensive medical cares as reflected by the high 
finance charges. As for those patients in Group 2, this population also responded very well to the 
therapies because the charges dropped sharply to low levels in the subsequent years. The 
charges, however, bounced back to low-medium level in 2012 and 2013. In the trajectory models 
developed using chargeR, a portion of patients (Group 6, 13.6%) did not response well to the 
medical intervention, and the ChargeF remained at high level during 5 years (Figure 11).  
The diagnostic analysis(Nagin, 2005) revealed a good capability of the trajectory model 
in estimating group memberships and assigning patients among the groups. Table 9 presented 
the appropriateness of the model assessed with four diagnostics standard. The lowest average 
posterior probability was 0.950, and the lowest value for the OCC was 59.2, far greater than the 
recommended values of 0.7 and 10, respectively. Furthermore, the estimated probability of group 
membership and the proportion of the patients assigned to each group are almost identical. 
Finally, the 95% confidences of the estimated group memberships were also reasonably narrow 
for each group; less than 0.025 plus or minus πj.  
Table 9. Model diagnostics for data using ChargeF. 
 
Trajectory 
Group 
Group 
Membership 
π 
95% 
Confidence 
Interval 
  
n 
 
AvePP* OCC* P* 
1 0.401 (0.386, 0.426)  640 0.989 126.1 0.4 
2 0.094 (0.079, 0.109)  152 0.953 195.8 0.095 
3 0.096 (0.080, 0.111)  152 0.952 186.2 0.095 
4 0.171 (0.151, 0.191)  275 0.958 110.5 0.172 
5 0.101 (0.085, 0.117)  163 0.946 154.6 0.102 
6 0.136 (0.119, 0.153)  218 0.971 214.9 0.136 
*AvePP, average Posterior Probability; OCC, odds of correct classification;  
P, actual proportion of subjects assigned to each trajectory group using the maximum probability rule. 
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4.0  DISCUSSION 
Through the use of group-based trajectory modeling we have identified distinct patterns of 
healthcare charges that are reflective of variations of disease activity, quality of life, healthcare 
utilization, and medication requirement for patients followed over a five-year time period. To our 
knowledge this is the first use of group-based trajectory modeling in financial data for an IBD 
patient population to reflect all-encompassing patterns of both the disease activity and patient 
experience of the disease.  
In this study, we first identified six distinct subgroups of patients by annual patterns of 
reduced healthcare charges (without biological medicine charge). The patterns could be 
summarized as persistently high (Group 6), chronically low (Group 1), and those with temporal 
variation (Groups 2-5). Demographic characteristics with significant variation among the 
established trajectory groups included CD (vs. UC or IBD-U), perianal involvement, extensive 
UC (vs. left-sided or proctitis), history of prior IBD surgery, comorbidities including psychiatric 
illness, diabetes mellitus, hypertension, as well as being unemployed. These demographic and 
disease associations are consistent with the previous studies. Several studies have demonstrated 
that CD to be in general more costly than UC (Yu et al., 2008) and that patients with more severe 
disease (perianal or extensive UC) carry a larger financial burden than those with mild or more 
limited disease (Feagan et al., 2000; Hillson et al., 2008; Silverstein et al., 1999). Furthermore, 
unemployment may simply be a reflection of patient disability secondary to severe IBD thus 
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leading to higher expenses (Ananthakrishnan et al., 2008). Similarly, the presence of multiple 
comorbid conditions has been shown to be associated with patients who utilize healthcare 
disproportionately (Gawande; Hempstead et al., 2014).  
The trajectory patterns are slightly different when the biological charges were included in 
the total annual charges, in particular, when we compare groups 2 and 3 with groups 4 and 5 
developed with reduced charges.  Clearly, a portion of the patients in group 3 in the full charge 
model were able to maintain remission under the biological therapy. Similarly, the bounce of 
financial charge in group 2 in 2012 and 2013 in the full charge model were likely due to the 
biological charges, indicating that some patients were able to achieve and maintain remission 
after the surgical care with the help of biological medicine.  
While some might view the reduced charge as a misrepresentation of the true costs of IBD 
patients, we believe it is a more realistic reflection of disease activity, healthcare utilization, and 
patient experience of disease. This could be exemplified by a patient in complete remission being 
maintained on an expensive biologic agent having roughly the same financial expenditures as a 
patient hospitalized and underwent a surgical resection for active disease. The financial charge 
alone could not differentiate these two disparate situations in term of disease processes and 
patient experiences as the two situations carry roughly the same expense. Thus, we elected to 
perform a sensitivity analysis of models with and without biologic charges. 
We further demonstrated that patterns of healthcare spending generated by group-based 
trajectory modeling are reflective of multiple dimensions of the chronic disease experience. First, 
patient patterns in spending are reflective of patterns in acute disease activity as measured by 
both patient-reported measures (HBI, UCAI) and biochemical markers of inflammation (hsCRP, 
ESR), and patients with the most persistently high or low financial charge totals also had the 
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most extreme measures of the disease activity. Secondly, patterns in spending echo healthcare 
utilization measures such as ED use, hospitalization, and surgery. The interpretation of this 
association, however, should be cautioned for likely collinearity, as these parameters produce a 
financial charge inherently. The trends in financial charges were also adequately reflective of the 
need for corticosteroid, a mainstay in the treatment for acute attacks of moderate to severe 
disease. Finally, financial charges were reflected by changes in quality of life of the IBD 
patients. Together, these trends suggest that financial charges can be an adequate and sensitive 
measure of disease activities, healthcare utilization, medication requirement, and quality of life, 
and may serve as and uniform gold standard for IBD disease severity. 
Like all other studies in the field, this one is also not free from limitations. First, conversion 
of continuous financial charges to categorical charges, regardless of how you do it, results in loss 
of power  in the subsequent statistical hypothesis testing (Aiken and West, 1991). These 
categories were not divided equally in this study. There are no good reasons in general to justify 
why the financial charge should be categorized as it was. Therefore, effect of using of different 
cutting points on trajectory groups should be examined in the future.  Second, the process of 
enrollment in the IBD registry and back-filling of data to 2009 allows for bias if patients were 
seen in another capacity at the UPMC but outside of gastroenterological care prior to enrollment 
in the IBD registry. This would result in financial charges while not receiving focused IBD care 
and thus may not accurately reflect the impact or their IBD course. We were not able to identify 
the first visit date at the IBD clinic to minimize this bias. We attempted to control for this 
possible confounding as we only included patients with five-year follow up, and excluded 
patients if charges in the first year were missing. Third, the use of observational data limits the 
data available for collection and analysis. There were a proportion of patients with missing 
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clinical data (n=63) as well as missing Montreal classification characterization (location n=47, 
perianal n=16, behavior n=79, extent n=89). We included these patients in the trajectory model 
development to avoid reduction in power and increase of variability. The missing data, however, 
is a potential source of bias when we compare the patients characteristics based on the 
established group memberships. In addition, patients with missing financial charge at 2009 or 
2013, or with missing data for more than one consecutive year were excluded from the model 
analysis. For those patients with charge data missing for a year but had charges in the 
surrounding years, we empirically set their missing charge to zero.  Clearly, these techniques of 
handling of missing data may lead to both bias and loss of power. A sensitivity analysis should 
be considered in the future study. Furthermore, though this was a temporal analysis of healthcare 
financial charges, disease and clinical parameters, certain variables that temporally vary were 
only available in a static measure (e.g. smoking). These dynamic changes may have influenced 
the progression of the disease. Lastly, the present study was a single institutional study at a 
tertiary referral center and thus the findings may not yet be generalizable to other populations or 
centers.  
Despite the potential limitations mentioned above, there are major strengths in this study. 
The use of a highly detailed observational natural history registry in a large cohort of IBD 
patients provides an accurate reflection of real-life clinical care in a tertiary center. This study is 
a multi-year longitudinal evaluation allowing for temporal variation in disease course in response 
to medical interventions. The association of financial charges to classic measures of disease 
activity, quality of life, healthcare utilization, and medication requirement implies that financial 
healthcare expenditures are perhaps the best all-encompassing measure of disease burden (both 
from an activity standpoint and a patient’s perspective) in the IBD. Thus, we believe that 
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financial burden can be used as a surrogate outcome measure to reflect a general global 
assessment of patient status.  
In conclusion, group-based trajectory modeling of financial charges in the IBD patients 
allows for identification of patient subgroups that mirrors overall disease course. Financial 
charges represent a novel and unique means of agnostic phenotyping in IBD. Combined with 
multinomial logistic regression, the trajectory model could also be used to determine the genetic 
and environmental factors that influence the responses of patients to the healthcare strategies. 
Further studies to quantify and clarify the effects of various clinical interventions on financial 
charges are needed to determine what treatment strategies are effective in subgroups of patients.  
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APPENDIX A. SAS CODE AND OUTPUT 
A.1 SAS CODE FOR THE REDUCED CHARGE MODEL 
 
/*import data set from excel file*/ 
proc import datafile = 'C:\mysas\Nobio040215_5yrs.xlsx' 
DBMS = EXCEL OUT = mysas.Nobio_5; 
GETNAMES=YES; 
MIXED=NO; 
SCANTEXT=YES; 
USEDATE=YES; 
SCANTIME=YES; 
run; 
 
 
/*convert continuous charges to categorical charges*/ 
Data Nobio_5; 
 set mysas.Nobio_5; 
 
 
  if c1=0    then cc1=0; 
  else if c1<=1000     then cc1=1; 
  else if c1<=2000     then cc1=2; 
  else if c1<=3000     then cc1=3; 
  else if c1<=4000     then cc1=4; 
  else if c1<=5000     then cc1=5; 
  else if c1<=6000     then cc1=6; 
  else if c1<=7500     then cc1=7; 
  else if c1<=9000     then cc1=8; 
  else if c1<=10500    then cc1=9; 
  else if c1<=12000    then cc1=10; 
  else if c1<=15000    then cc1=11; 
  else if c1<=18000    then cc1=12; 
  else if c1<=21000    then cc1=13; 
  else if c1<=24000    then cc1=14; 
  else if c1<=27000    then cc1=15; 
  else if c1<=30000    then cc1=16; 
  else if c1<=33000    then cc1=17; 
  else if c1<=36000    then cc1=18; 
  else if c1<=40000    then cc1=19; 
  else if c1<=45000    then cc1=20; 
  else if c1<=50000    then cc1=21; 
  else if c1<=55000    then cc1=22; 
  else if c1<=60000    then cc1=23; 
  else if c1<=70000    then cc1=24; 
  else if c1<=80000    then cc1=25; 
  else if c1<=90000    then cc1=26; 
  else if c1<=100000   then cc1=27; 
  else if c1<=120000   then cc1=28; 
  else if c1<=140000   then cc1=29; 
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  else if c1<=160000   then cc1=30; 
  else if c1<=180000   then cc1=31; 
  else if c1<=200000   then cc1=32; 
  else if c1<=250000   then cc1=33; 
  else if c1<=300000   then cc1=34; 
  else if c1<=350000   then cc1=35; 
  else if c1<=400000   then cc1=36; 
  else if c1<=450000   then cc1=37; 
  else if c1<=500000   then cc1=38; 
  else if c1<=1000000  then cc1=39; 
  else cc1=40; 
 
  
  if c2=0    then cc2=0; 
  else if c2<=1000     then cc2=1; 
  else if c2<=2000     then cc2=2; 
  else if c2<=3000     then cc2=3; 
  else if c2<=4000     then cc2=4; 
  else if c2<=5000     then cc2=5; 
  else if c2<=6000     then cc2=6; 
  else if c2<=7500     then cc2=7; 
  else if c2<=9000     then cc2=8; 
  else if c2<=10500    then cc2=9; 
  else if c2<=12000    then cc2=10; 
  else if c2<=15000    then cc2=11; 
  else if c2<=18000    then cc2=12; 
  else if c2<=21000    then cc2=13; 
  else if c2<=24000    then cc2=14; 
  else if c2<=27000    then cc2=15; 
  else if c2<=30000    then cc2=16; 
  else if c2<=33000    then cc2=17; 
  else if c2<=36000    then cc2=18; 
  else if c2<=40000    then cc2=19; 
  else if c2<=45000    then cc2=20; 
  else if c2<=50000    then cc2=21; 
  else if c2<=55000    then cc2=22; 
  else if c2<=60000    then cc2=23; 
  else if c2<=70000    then cc2=24; 
  else if c2<=80000    then cc2=25; 
  else if c2<=90000    then cc2=26; 
  else if c2<=100000   then cc2=27; 
  else if c2<=120000   then cc2=28; 
  else if c2<=140000   then cc2=29; 
  else if c2<=160000   then cc2=30; 
  else if c2<=180000   then cc2=31; 
  else if c2<=200000   then cc2=32; 
  else if c2<=250000   then cc2=33; 
  else if c2<=300000   then cc2=34; 
  else if c2<=350000   then cc2=35; 
  else if c2<=400000   then cc2=36; 
  else if c2<=450000   then cc2=37; 
  else if c2<=500000   then cc2=38; 
  else if c2<=1000000  then cc2=39; 
  else cc2=40; 
 
if c3=0         then cc3=0; 
  else if c3<=1000     then cc3=1; 
  else if c3<=2000     then cc3=2; 
  else if c3<=3000     then cc3=3; 
  else if c3<=4000     then cc3=4; 
  else if c3<=5000     then cc3=5; 
  else if c3<=6000     then cc3=6; 
  else if c3<=7500     then cc3=7; 
  else if c3<=9000     then cc3=8; 
  else if c3<=10500    then cc3=9; 
  else if c3<=12000    then cc3=10; 
  else if c3<=15000    then cc3=11; 
  else if c3<=18000    then cc3=12; 
  else if c3<=21000    then cc3=13; 
  else if c3<=24000    then cc3=14; 
  else if c3<=27000    then cc3=15; 
39 
  else if c3<=30000    then cc3=16; 
  else if c3<=33000    then cc3=17; 
  else if c3<=36000    then cc3=18; 
  else if c3<=40000    then cc3=19; 
  else if c3<=45000    then cc3=20; 
  else if c3<=50000    then cc3=21; 
  else if c3<=55000    then cc3=22; 
  else if c3<=60000    then cc3=23; 
  else if c3<=70000    then cc3=24; 
  else if c3<=80000    then cc3=25; 
  else if c3<=90000    then cc3=26; 
  else if c3<=100000   then cc3=27; 
  else if c3<=120000   then cc3=28; 
  else if c3<=140000   then cc3=29; 
  else if c3<=160000   then cc3=30; 
  else if c3<=180000   then cc3=31; 
  else if c3<=200000   then cc3=32; 
  else if c3<=250000   then cc3=33; 
  else if c3<=300000   then cc3=34; 
  else if c3<=350000   then cc3=35; 
  else if c3<=400000   then cc3=36; 
  else if c3<=450000   then cc3=37; 
  else if c3<=500000   then cc3=38; 
  else if c3<=1000000  then cc3=39; 
  else cc3=40; 
 
if c4=0    then cc4=0; 
  else if c4<=1000     then cc4=1; 
  else if c4<=2000     then cc4=2; 
  else if c4<=3000     then cc4=3; 
  else if c4<=4000     then cc4=4; 
  else if c4<=5000     then cc4=5; 
  else if c4<=6000     then cc4=6; 
  else if c4<=7500     then cc4=7; 
  else if c4<=9000     then cc4=8; 
  else if c4<=10500    then cc4=9; 
  else if c4<=12000    then cc4=10; 
  else if c4<=15000    then cc4=11; 
  else if c4<=18000    then cc4=12; 
  else if c4<=21000    then cc4=13; 
  else if c4<=24000    then cc4=14; 
  else if c4<=27000    then cc4=15; 
  else if c4<=30000    then cc4=16; 
  else if c4<=33000    then cc4=17; 
  else if c4<=36000    then cc4=18; 
  else if c4<=40000    then cc4=19; 
  else if c4<=45000    then cc4=20; 
  else if c4<=50000    then cc4=21; 
  else if c4<=55000    then cc4=22; 
  else if c4<=60000    then cc4=23; 
  else if c4<=70000    then cc4=24; 
  else if c4<=80000    then cc4=25; 
  else if c4<=90000    then cc4=26; 
  else if c4<=100000   then cc4=27; 
  else if c4<=120000   then cc4=28; 
  else if c4<=140000   then cc4=29; 
  else if c4<=160000   then cc4=30; 
  else if c4<=180000   then cc4=31; 
  else if c4<=200000   then cc4=32; 
  else if c4<=250000   then cc4=33; 
  else if c4<=300000   then cc4=34; 
  else if c4<=350000   then cc4=35; 
  else if c4<=400000   then cc4=36; 
  else if c4<=450000   then cc4=37; 
  else if c4<=500000   then cc4=38; 
  else if c4<=1000000  then cc4=39; 
  else cc4=40; 
 
if c5=0   then cc5=0; 
  else if c5<=1000     then cc5=1; 
  else if c5<=2000     then cc5=2; 
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  else if c5<=3000     then cc5=3; 
  else if c5<=4000     then cc5=4; 
  else if c5<=5000     then cc5=5; 
  else if c5<=6000     then cc5=6; 
  else if c5<=7500     then cc5=7; 
  else if c5<=9000     then cc5=8; 
  else if c5<=10500    then cc5=9; 
  else if c5<=12000    then cc5=10; 
  else if c5<=15000    then cc5=11; 
  else if c5<=18000    then cc5=12; 
  else if c5<=21000    then cc5=13; 
  else if c5<=24000    then cc5=14; 
  else if c5<=27000    then cc5=15; 
  else if c5<=30000    then cc5=16; 
  else if c5<=33000    then cc5=17; 
  else if c5<=36000    then cc5=18; 
  else if c5<=40000    then cc5=19; 
  else if c5<=45000    then cc5=20; 
  else if c5<=50000    then cc5=21; 
  else if c5<=55000    then cc5=22; 
  else if c5<=60000    then cc5=23; 
  else if c5<=70000    then cc5=24; 
  else if c5<=80000    then cc5=25; 
  else if c5<=90000    then cc5=26; 
  else if c5<=100000   then cc5=27; 
  else if c5<=120000   then cc5=28; 
  else if c5<=140000   then cc5=29; 
  else if c5<=160000   then cc5=30; 
  else if c5<=180000   then cc5=31; 
  else if c5<=200000   then cc5=32; 
  else if c5<=250000   then cc5=33; 
  else if c5<=300000   then cc5=34; 
  else if c5<=350000   then cc5=35; 
  else if c5<=400000   then cc5=36; 
  else if c5<=450000   then cc5=37; 
  else if c5<=500000   then cc5=38; 
  else if c5<=1000000  then cc5=39; 
  else cc5=40; 
 run; 
 
/*Frequency distribution of categorical charges*/ 
proc sgplot data=Nobio_5; 
vbar cc1; 
run; 
proc sgplot data=Nobio_5; 
vbar cc2; 
run; 
proc sgplot data=Nobio_5; 
vbar cc3; 
run; 
proc sgplot data=Nobio_5; 
vbar cc4; 
run; 
proc sgplot data=Nobio_5; 
vbar cc5; 
run; 
 
/*obtain descriptive statistics for total annual charge*/ 
proc univariate data=Nobio_5; 
var total2009 total2010 total2011 total2012 total2013; 
 histogram total2009 total2010 total2011 total2012 total2013; 
run; 
 
/*group based trajectory analysis, final model*/ 
PROC TRAJ DATA=Nobio_5 OUTPLOT=OP OUTSTAT=OS OUT=OF OUTEST=OE ITDETAIL; 
    ID ID; VAR cc1-cc5; INDEP T1-T5; 
    MODEL ZIP; NGROUPS 6; ORDER 0 2 3 3 3 1; IORDER 2; 
RUN; 
 
%TRAJPLOT(OP,OS,'Charges vs. Time','ZIP Model','charges','Time, Year') 
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A.2 SAS OUTPUT FOR THE FINAL ZIP MODEL USING REDUCED FINANCIAL 
CHARGE  
Maximum Likelihood Estimates 
                        Model: Zero Inflated Poisson (ZIP) 
 
                                   Standard       T for H0: 
 Group   Parameter    Estimate        Error     Parameter=0   Prob > |T| 
 
 1       Intercept     0.88201      0.01331          66.248       0.0000 
 
 2       Intercept     1.73373      0.11212          15.463       0.0000 
         Linear       -0.70612      0.07817          -9.033       0.0000 
         Quadratic     0.19844      0.01204          16.483       0.0000 
 
 3       Intercept     7.00765      0.22136          31.657       0.0000 
         Linear       -5.50242      0.32160         -17.110       0.0000 
         Quadratic     1.74314      0.12021          14.501       0.0000 
         Cubic        -0.17330      0.01325         -13.076       0.0000 
 
 4       Intercept     1.40392      0.18163           7.729       0.0000 
         Linear       -1.03631      0.21533          -4.813       0.0000 
         Quadratic     0.86111      0.07645          11.263       0.0000 
         Cubic        -0.13019      0.00838         -15.534       0.0000 
 
 5       Intercept    -2.87687      0.24584         -11.702       0.0000 
         Linear        7.53492      0.28196          26.723       0.0000 
         Quadratic    -2.86484      0.10206         -28.069       0.0000 
         Cubic         0.30810      0.01131          27.242       0.0000 
 
 6       Intercept     2.94690      0.02407         122.408       0.0000 
         Linear        0.03498      0.00746           4.687       0.0000 
 
         Alpha0       -6.23055      0.43051         -14.473       0.0000 
         Alpha1        1.88658      0.26125           7.221       0.0000 
         Alpha2       -0.21336      0.03800          -5.615       0.0000 
 
         Group membership 
 1             (%)    52.10149      1.29442          40.251       0.0000 
 2             (%)     8.06928      0.72653          11.107       0.0000 
 3             (%)     9.34635      0.78552          11.898       0.0000 
 4             (%)    12.12111      0.88423          13.708       0.0000 
 5             (%)     9.35572      0.76501          12.230       0.0000 
 6             (%)     9.00605      0.74000          12.170       0.0000 
 
 BIC=-27050.85 (N=8000)  BIC=-27029.93 (N=1600)  AIC=-26960.02  L=-26934.02 
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A.3 SAS CODE FOR THE FULL FINANCIAL CHARGE MODEL  
 
 
/*group based trajectory analysis using full charge, final model*/ 
PROC TRAJ DATA=sortID_5 OUTPLOT=OP OUTSTAT=OS OUT=OF OUTEST=OE ITDETAIL; 
    ID ID; VAR cc1-cc5; INDEP T1-T5; 
    MODEL ZIP; NGROUPS 6; ORDER 3 3 3 3 3 1; IORDER 1; 
RUN; 
 
%TRAJPLOT(OP,OS,'Charges vs. Time','ZIP Model','charges','Time, Year') 
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A.4 SAS OUTPUT FOR THE FINAL ZIP MODEL USING FULL FINANCIAL 
CHARGE  
 
                        Maximum Likelihood Estimates 
                        Model: Zero Inflated Poisson (ZIP) 
 
                                   Standard       T for H0: 
 Group   Parameter    Estimate        Error     Parameter=0   Prob > |T| 
 
 1       Intercept     1.74982      0.14155          12.361       0.0000 
         Linear       -1.06537      0.18872          -5.645       0.0000 
         Quadratic     0.34698      0.07081           4.900       0.0000 
         Cubic        -0.03416      0.00789          -4.329       0.0000 
 
 2       Intercept    -1.86553      0.18598         -10.031       0.0000 
         Linear        5.45221      0.22333          24.413       0.0000 
         Quadratic    -1.93518      0.08525         -22.699       0.0000 
         Cubic         0.19464      0.00979          19.878       0.0000 
 
 3       Intercept    -1.61189      0.21033          -7.663       0.0000 
         Linear        3.83442      0.23018          16.659       0.0000 
         Quadratic    -1.02615      0.07815         -13.131       0.0000 
         Cubic         0.08743      0.00817          10.701       0.0000 
 
 4       Intercept     2.82371      0.21867          12.913       0.0000 
         Linear       -2.97808      0.26665         -11.168       0.0000 
         Quadratic     1.27351      0.08986          14.172       0.0000 
         Cubic        -0.13623      0.00907         -15.023       0.0000 
 
 5       Intercept     7.47794      0.19880          37.615       0.0000 
         Linear       -6.37780      0.28656         -22.256       0.0000 
         Quadratic     2.06293      0.10650          19.370       0.0000 
         Cubic        -0.19957      0.01152         -17.318       0.0000 
 
 6       Intercept     3.19755      0.01948         164.104       0.0000 
         Linear       -0.08302      0.00673         -12.335       0.0000 
 
         Alpha0       -4.47524      0.18692         -23.942       0.0000 
         Alpha1        0.50738      0.04554          11.141       0.0000 
 
         Group membership 
 1             (%)    40.11527      1.25678          31.919       0.0000 
 2             (%)     9.44210      0.77658          12.159       0.0000 
 3             (%)     9.56050      0.79306          12.055       0.0000 
 4             (%)    17.14981      1.00953          16.988       0.0000 
 5             (%)    10.12066      0.79872          12.671       0.0000 
 6             (%)    13.61167      0.89121          15.273       0.0000 
 
 BIC=-28620.09 (N=8000)  BIC=-28596.75 (N=1600)  AIC=-28518.77  L=-28489.77 
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